| 摘要 |
The present invention relates to a pharmaceutical composition comprising dapoxetine or a pharmaceutically acceptable salt thereof as an active ingredient for treating pain. More specifically, the dapoxetine inhibits the voltage-dependent sodium channel 1.7 (hNav1.7) of humans. As the dapoxetine developed for treating premature ejaculation is identified to concentration dependently inhibit the voltage dependent sodium channel 1.7 (Nav1.7) which is known as a pain gene of human, the dapoxetine is expected to be valuably used as a therapeutic agent for pain. |
